Oncodesign Precision Medicine

ALOPM.PAPhase 2

Dijon, FranceFounded 1995oncodesign.com

Oncodesign Precision Medicine is a publicly traded biotech focused on developing innovative therapeutic and diagnostic solutions for resistant cancers and neurodegenerative diseases. Its core strength lies in the Nanocyclix® platform, which generates highly selective macrocyclic kinase inhibitors, enabling a pipeline with first-in-class and best-in-class potential. The company has secured strategic validation and funding from The Michael J. Fox Foundation for its Parkinson's program and is advancing multiple clinical-stage assets while exploring radiotheranostic approaches through collaborative projects like COMETE.

Market Cap

$10.0M

Founded

1995

Focus

Small Molecules

ALOPM.PA · Stock Price

USD 0.470.38 (-44.71%)

Historical price data

AI Company Overview

Technology Platform

Nanocyclix® platform for discovering small macrocyclic kinase inhibitors; OncoSNIPER AI platform for target identification and validation; PROMETHE® collaborative innovation ecosystem.

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage
OPM-101	Advanced Melanoma	Phase 1/2

Funding History

Total raised: $10.5M

IPO$10.5MUndisclosedJul 9, 2014

Opportunities

Major opportunities include successfully advancing OPM-101 as a novel combo therapy in the massive immuno-oncology market, capturing a niche in Parkinson's disease with a potentially best-in-class LRRK2 inhibitor, and leveraging the emerging radiotheranostics field through the COMETE project.

The company's validated platform also presents ongoing partnering and out-licensing potential.

Risk Factors

Key risks include clinical trial failures for lead assets, the need for substantial additional capital to fund later-stage development, intense competition in the Parkinson's disease space from more advanced competitors, and execution risk in securing value-creating partnerships for its programs.

Competitive Landscape

OPM-101 faces limited direct competition as a first-in-class RIPK2 inhibitor but must prove efficacy against standard of care. OPM-201 competes with Denali/Biogen's DNL-151 and Neuron23's NEU-411 in the LRRK2 space, requiring differentiation through its genetic variant-focused strategy and potential best-in-class profile. The COMETE project competes in the broader radiopharmaceutical arena but aims to differentiate via novel AI-identified targets.